You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemozolomide
Accession NumberDB00853  (APRD00557)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTemozolomide (Temodar and Temodal) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumor. Temozolomide is not active until it is converted at physiologic pH to the active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC).
Structure
Thumb
Synonyms
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
M&B 39831
MB 39831
Methazolastone
NSC 362856
Sch 52365
Temodal
Temodar
Temozolodida
Temozolomid
Temozolomida
Témozolomide
Temozolomidum
TMZ
External Identifiers
  • BRN 5547136
  • CCRG 81045
  • M & B 39831
  • NSC 362856
  • SCH 52365
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-temozolomideCapsule180 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Ach-temozolomideCapsule5 mgOralAccord Healthcare Limited2016-01-13Not applicableCanada
Ach-temozolomideCapsule20 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Ach-temozolomideCapsule250 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Ach-temozolomideCapsule100 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Ach-temozolomideCapsule140 mgOralAccord Healthcare Limited2012-07-25Not applicableCanada
Act TemozolomideCapsule140 mgOralActavis Pharma Company2012-11-07Not applicableCanada
Act TemozolomideCapsule250 mgOralActavis Pharma Company2012-11-07Not applicableCanada
Act TemozolomideCapsule20 mgOralActavis Pharma Company2012-11-07Not applicableCanada
Act TemozolomideCapsule5 mgOralActavis Pharma Company2015-12-08Not applicableCanada
Act TemozolomideCapsule180 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act TemozolomideCapsule100 mgOralActavis Pharma Company2012-11-07Not applicableCanada
Taro-temozolomideCapsule5 mgOralTaro Pharmaceuticals, Inc.2015-07-23Not applicableCanada
Taro-temozolomideCapsule250 mgOralTaro Pharmaceuticals, Inc.2015-07-23Not applicableCanada
Taro-temozolomideCapsule20 mgOralTaro Pharmaceuticals, Inc.2015-07-23Not applicableCanada
Taro-temozolomideCapsule180 mgOralTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada
Taro-temozolomideCapsule100 mgOralTaro Pharmaceuticals, Inc.2015-07-23Not applicableCanada
Taro-temozolomideCapsule140 mgOralTaro Pharmaceuticals, Inc.2015-07-23Not applicableCanada
TemodalCapsule250 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalInjection, powder, for solution2.5 mg/mlIntravenousMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule140 mgOralMerck Ltd.2009-02-21Not applicableCanada
TemodalCapsule5 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule100 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule180 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule20 mgOralMerck Ltd.1999-11-12Not applicableCanada
TemodalCapsule100 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule180 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule140 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule5 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule5 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule140 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule20 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule100 mgOralMerck Ltd.1999-11-12Not applicableCanada
TemodalCapsule100 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule250 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalPowder, for solution100 mgIntravenousMerck Ltd.2009-12-102016-02-01Canada
TemodalCapsule140 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule5 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule20 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule140 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule180 mgOralMerck Ltd.2009-02-212011-07-22Canada
TemodalCapsule20 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule250 mgOralMerck Ltd.1999-11-12Not applicableCanada
TemodalCapsule250 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule250 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule180 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule5 mgOralMerck Ltd.1999-11-12Not applicableCanada
TemodalCapsule20 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule180 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodalCapsule100 mgOralMerck Sharp & Dohme Limited  1999-01-26Not applicableEu
TemodarCapsule100 mg/1OralPhysicians Total Care, Inc.2005-10-07Not applicableUs
TemodarCapsule100 mg/1OralMerck Sharp & Dohme Limited  1999-08-11Not applicableUs
TemodarCapsule180 mg/1OralMerck Sharp & Dohme Limited  1999-08-11Not applicableUs
TemodarInjection, powder, lyophilized, for solution2.5 mg/mLIntravenousMerck Sharp & Dohme Limited  2009-02-27Not applicableUs
TemodarCapsule250 mg/1OralPhysicians Total Care, Inc.2006-04-13Not applicableUs
TemodarCapsule20 mg/1OralMerck Sharp & Dohme Limited  1999-08-11Not applicableUs
TemodarCapsule250 mg/1OralMerck Sharp & Dohme Limited  1999-08-11Not applicableUs
TemodarCapsule180 mg/1OralPhysicians Total Care, Inc.2009-01-26Not applicableUs
TemodarCapsule20 mg/1OralPhysicians Total Care, Inc.2005-06-29Not applicableUs
TemodarCapsule5 mg/1OralMerck Sharp & Dohme Limited  1999-08-11Not applicableUs
TemodarCapsule140 mg/1OralMerck Sharp & Dohme Limited  1999-08-11Not applicableUs
TemodarCapsule5 mg/1OralPhysicians Total Care, Inc.2005-10-20Not applicableUs
TemozolomideCapsule5 mg/1OralSandoz2013-08-12Not applicableUs
TemozolomideCapsule180 mg/1OralSandoz2013-08-12Not applicableUs
TemozolomideCapsule20 mg/1OralSandoz2013-08-12Not applicableUs
TemozolomideCapsule250 mg/1OralSandoz2013-08-12Not applicableUs
TemozolomideCapsule100 mg/1OralSandoz2013-08-12Not applicableUs
TemozolomideCapsule140 mg/1OralSandoz2013-08-12Not applicableUs
Temozolomide CapsulesCapsule5 mgOralMda Inc.Not applicableNot applicableCanada
Temozolomide CapsulesCapsule20 mgOralMda Inc.Not applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-temozolomideCapsule100 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule140 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule180 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule5 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule250 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-temozolomideCapsule20 mgOralApotex CorporationNot applicableNot applicableCanada
Emozolomide AccordCapsule140 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule20 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule250 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule250 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule140 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule20 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule5 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule140 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule100 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule5 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule250 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule180 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule100 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule5 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule180 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule100 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule5 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule180 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule20 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule100 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule180 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule140 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule20 mgOralHospira, Inc.2010-03-15Not applicableEu
Emozolomide AccordCapsule250 mgOralHospira, Inc.2010-03-15Not applicableEu
TemomedacCapsule5 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule180 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule100 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule5 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule180 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule100 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule20 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule250 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule140 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule20 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule250 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemomedacCapsule140 mgOralMedac Gesellschaft Für Klinische Spezialpräparate Mb H2010-01-25Not applicableEu
TemozolomideCapsule140 mg/1OralKremers Urban2016-02-10Not applicableUs
TemozolomideCapsule140 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-08-01Not applicableUs
TemozolomideCapsule5 mg/1OralAmneal Pharmaceuticals2015-04-03Not applicableUs
TemozolomideCapsule20 mg/1OralSun Pharma Global FZE2014-02-13Not applicableUs
TemozolomideCapsule100 mg/1OralMylan Pharmaceuticals2016-06-29Not applicableUs
TemozolomideCapsule250 mg/1OralAmerigen Pharmaceuticals Inc.2016-07-13Not applicableUs
TemozolomideCapsule250 mg/1OralRoxane Laboratories2016-03-24Not applicableUs
TemozolomideCapsule5 mg/1OralTeva2013-08-12Not applicableUs
TemozolomideCapsule180 mg/1OralSun Pharma Global FZE2014-02-13Not applicableUs
TemozolomideCapsule20 mg/1OralRoxane Laboratories2016-03-24Not applicableUs
TemozolomideCapsule20 mg/1OralAmerigen Pharmaceuticals Inc.2016-07-13Not applicableUs
TemozolomideCapsule180 mg/1OralAmneal Pharmaceuticals2015-04-03Not applicableUs
TemozolomideCapsule140 mg/1OralLannett Company, Inc.2016-03-23Not applicableUs
TemozolomideCapsule140 mg/1OralTeva2013-08-12Not applicableUs
TemozolomideCapsule5 mg/1OralKremers Urban2016-02-10Not applicableUs
TemozolomideCapsule5 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-08-01Not applicableUs
TemozolomideCapsule140 mg/1OralMayne Pharma2016-10-10Not applicableUs
TemozolomideCapsule180 mg/1OralKremers Urban2016-02-10Not applicableUs
TemozolomideCapsule180 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-08-01Not applicableUs
TemozolomideCapsule20 mg/1OralAmneal Pharmaceuticals2015-04-03Not applicableUs
TemozolomideCapsule100 mg/1OralSun Pharma Global FZE2014-02-13Not applicableUs
TemozolomideCapsule20 mg/1OralTeva2013-08-12Not applicableUs
TemozolomideCapsule140 mg/1OralMylan Pharmaceuticals2016-06-29Not applicableUs
TemozolomideCapsule5 mg/1OralMayne Pharma2016-10-10Not applicableUs
TemozolomideCapsule5 mg/1OralLannett Company, Inc.2016-03-23Not applicableUs
TemozolomideCapsule140 mg/1OralAvera Mc Kennan Hospital2015-06-11Not applicableUs
TemozolomideCapsule100 mg/1OralRoxane Laboratories2016-03-24Not applicableUs
TemozolomideCapsule100 mg/1OralAmerigen Pharmaceuticals Inc.2016-07-13Not applicableUs
TemozolomideCapsule250 mg/1OralAmneal Pharmaceuticals2015-04-03Not applicableUs
TemozolomideCapsule180 mg/1OralLannett Company, Inc.2016-03-23Not applicableUs
TemozolomideCapsule180 mg/1OralTeva2013-08-12Not applicableUs
TemozolomideCapsule20 mg/1OralKremers Urban2016-02-10Not applicableUs
TemozolomideCapsule20 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-08-01Not applicableUs
TemozolomideCapsule180 mg/1OralMayne Pharma2016-10-10Not applicableUs
TemozolomideCapsule250 mg/1OralSun Pharma Global FZE2014-02-13Not applicableUs
TemozolomideCapsule250 mg/1OralKremers Urban2016-02-10Not applicableUs
TemozolomideCapsule250 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-08-01Not applicableUs
TemozolomideCapsule100 mg/1OralAmneal Pharmaceuticals2015-04-03Not applicableUs
TemozolomideCapsule100 mg/1OralTeva2013-08-12Not applicableUs
TemozolomideCapsule180 mg/1OralMylan Pharmaceuticals2016-06-29Not applicableUs
TemozolomideCapsule20 mg/1OralMayne Pharma2016-10-10Not applicableUs
TemozolomideCapsule20 mg/1OralLannett Company, Inc.2016-03-23Not applicableUs
TemozolomideCapsule5 mg/1OralMylan Pharmaceuticals2016-06-29Not applicableUs
TemozolomideCapsule140 mg/1OralRoxane Laboratories2016-03-24Not applicableUs
TemozolomideCapsule140 mg/1OralAmerigen Pharmaceuticals Inc.2016-07-13Not applicableUs
TemozolomideCapsule250 mg/1OralLannett Company, Inc.2016-03-23Not applicableUs
TemozolomideCapsule5 mg/1OralSun Pharma Global FZE2014-02-13Not applicableUs
TemozolomideCapsule100 mg/1OralKremers Urban2016-02-10Not applicableUs
TemozolomideCapsule100 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-08-01Not applicableUs
TemozolomideCapsule250 mg/1OralMayne Pharma2016-10-10Not applicableUs
TemozolomideCapsule140 mg/1OralSun Pharma Global FZE2014-02-13Not applicableUs
TemozolomideCapsule5 mg/1OralRoxane Laboratories2016-03-24Not applicableUs
TemozolomideCapsule5 mg/1OralAmerigen Pharmaceuticals Inc.2016-07-13Not applicableUs
TemozolomideCapsule140 mg/1OralAmneal Pharmaceuticals2015-04-03Not applicableUs
TemozolomideCapsule100 mg/1OralLannett Company, Inc.2016-03-23Not applicableUs
TemozolomideCapsule250 mg/1OralTeva2013-08-12Not applicableUs
TemozolomideCapsule250 mg/1OralMylan Pharmaceuticals2016-06-29Not applicableUs
TemozolomideCapsule100 mg/1OralMayne Pharma2016-10-10Not applicableUs
TemozolomideCapsule20 mg/1OralMylan Pharmaceuticals2016-06-29Not applicableUs
TemozolomideCapsule180 mg/1OralRoxane Laboratories2016-03-24Not applicableUs
TemozolomideCapsule180 mg/1OralAmerigen Pharmaceuticals Inc.2016-07-13Not applicableUs
Temozolomide HexalCapsule180 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule5 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule20 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule100 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule5 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule180 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule140 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule180 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule20 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule250 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule20 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule140 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule20 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule250 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule140 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule250 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule250 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule100 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule100 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule140 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule20 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule5 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule180 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule250 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule5 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule140 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule100 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule180 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule100 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide HexalCapsule5 mgOralHexal Ag  2010-03-15Not applicableEu
Temozolomide SandozCapsule180 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule20 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule100 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule5 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule140 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule180 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule250 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule20 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule140 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule20 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule140 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule250 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule250 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule100 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule140 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule20 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule5 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule180 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule250 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule5 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule100 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule180 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule100 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SandozCapsule5 mgOralSandoz2010-03-15Not applicableEu
Temozolomide SunCapsule5 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule20 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule180 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule250 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule100 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule140 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule5 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule5 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule100 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule180 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule100 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule180 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule5 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule20 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule100 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule250 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule140 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule180 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule20 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule20 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule140 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule250 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule140 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide SunCapsule250 mgOralSun Pharmaceutical Industries (Europe) B.V.2011-07-13Not applicableEu
Temozolomide TevaCapsule140 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule250 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule20 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule140 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule5 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule250 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule100 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule180 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule5 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule100 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule180 mgOralTeva B.V.  2010-01-28Not applicableEu
Temozolomide TevaCapsule20 mgOralTeva B.V.  2010-01-28Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIYF1K15M17Y
CAS number85622-93-1
WeightAverage: 194.1508
Monoisotopic: 194.055223466
Chemical FormulaC6H6N6O2
InChI KeyBPEGJWRSRHCHSN-UHFFFAOYSA-N
InChI
InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
IUPAC Name
3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide
SMILES
CN1N=NC2=C(N=CN2C1=O)C(N)=O
Pharmacology
IndicationFor the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme.
Structured Indications
Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentHigh Grade Glioma (HGG)1
0RecruitingDiagnosticBlood Brain Barrier Defect1
0RecruitingTreatmentAstrocytoma, Grade IV / Glioblastoma Multiforme1
1Active Not RecruitingTreatmentAccelerated Phase of Disease / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult T Acute Lymphoblastic Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Blastic Phase / Chronic Myelomonocytic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Disease / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Neoplasm1
1Active Not RecruitingTreatmentAdvanced Solid Tumors1
1Active Not RecruitingTreatmentBrain Cancer1
1Active Not RecruitingTreatmentBrain and Central Nervous System Tumors3
1Active Not RecruitingTreatmentGBM / Glioblastoma Multiforme / Glioblastomas1
1Active Not RecruitingTreatmentGlioblastoma Multiforme3
1Active Not RecruitingTreatmentGlioblastoma Multiforme / Gliosarcoma / Tumor, Brain1
1Active Not RecruitingTreatmentGlioblastomas3
1Active Not RecruitingTreatmentMelanoma1
1Active Not RecruitingTreatmentMelanoma (Skin)2
1Active Not RecruitingTreatmentMetastatic Cancers / Unspecified Adult Solid Tumor1
1Active Not RecruitingTreatmentMetastatic Melanoma1
1Active Not RecruitingTreatmentNeuroblastomas1
1Active Not RecruitingTreatmentRectal Cancers1
1Active Not RecruitingTreatmentTumors, Central Nervous System1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAcoustic Schwannoma / Adult Anaplastic (Malignant) Meningioma / Adult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Brain Stem Glioma / Adult Choroid Plexus Neoplasm / Adult Craniopharyngioma / Adult Diffuse Astrocytoma / Adult Ependymoblastoma / Adult Ependymoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Grade I Meningioma / Adult Grade II Meningioma / Adult Medulloblastoma / Adult Mixed Glioma / Adult Myxopapillary Ependymoma / Adult Oligodendroglioma / Adult Papillary Meningioma / Adult Pilocytic Astrocytoma / Adult Pineal Gland Astrocytoma / Adult Pineoblastoma / Adult Pineocytoma / Adult Primary Melanocytic Lesion of Meninges / Adult Subependymal Giant Cell Astrocytoma / Adult Subependymoma / Adult Supratentorial Primitive Neuroectodermal Tumor / Malignant Adult Intracranial Hemangiopericytoma1
1CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Tumor1
1CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma3
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas / Gliosarcoma2
1CompletedTreatmentAstrocytomas / Ependymomas / Medulloblastomas / PNET / Pontine Glioma1
1CompletedTreatmentBrain and Central Nervous System Tumors11
1CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Kidney Cancer / Liver Cancer / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Kidney Cancer / Liver Cancer / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS / Metastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBrain and Central Nervous System Tumors / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Fallopian Tube Cancer / Hepatocellular Carcinomas / Metastatic Melanoma / Non-hematologic Malignancies / Primary Peritoneal Cancer1
1CompletedTreatmentCancers / Chronic Lung Diseases1
1CompletedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Extra-Adrenal Paraganglioma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentChildhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentDiarrhea / Drug/Agent Toxicity by Tissue/Organ / Neuroblastomas1
1CompletedTreatmentGiant Cell Glioblastoma / Glioblastomas / Gliosarcoma1
1CompletedTreatmentGlioblastoma Multiforme / Malignant Gliomas / Mixed Gliomas1
1CompletedTreatmentGlioblastoma Multiforme / Melanoma / Recurrence of Solid Tumor1
1CompletedTreatmentGlioblastomas3
1CompletedTreatmentGlioblastomas / Gliosarcoma3
1CompletedTreatmentHER2 Positive / Metastases, Brain / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentLeukemias2
1CompletedTreatmentMalignant Neoplasms of Brain1
1CompletedTreatmentMalignant Tumors / Refractory Tumors1
1CompletedTreatmentMelanoma2
1CompletedTreatmentMelanoma / Neoplasms, Brain1
1CompletedTreatmentMetastases, Brain / Primary Brain Tumors1
1CompletedTreatmentMetastatic Melanoma1
1CompletedTreatmentPreviously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Neuroblastoma / Recurrent Osteosarcoma1
1CompletedTreatmentProstate Cancers1
1CompletedTreatmentRefractory Solid Tumors in Children1
1CompletedTreatmentTumor, Brain / Tumors, Central Nervous System1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific4
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentGlioblastoma Multiforme1
1Not Yet RecruitingTreatmentMalignant Glioma of Brain1
1RecruitingTreatmentAdult Brain Glioblastoma / Adult Giant Cell Glioblastoma / Adult Gliosarcoma1
1RecruitingTreatmentAdult Glioblastoma / Recurrent Adult Brain Neoplasm / Recurrent Glioblastoma1
1RecruitingTreatmentAstrocytoma, Grade IV / Glioblastomas1
1RecruitingTreatmentBrain and Central Nervous System Tumors1
1RecruitingTreatmentCancer, Advanced / Tumors, Solid1
1RecruitingTreatmentChildhood Solid Tumors1
1RecruitingTreatmentEpendymomas / Glioblastoma Multiforme / Gliomas / Gliosarcoma / Malignant Brain Tumors / Medulloblastomas1
1RecruitingTreatmentGlioblastoma Multiforme2
1RecruitingTreatmentGlioblastoma Multiforme/Anaplastic Astrocytoma1
1RecruitingTreatmentGlioblastoma Multiforme / Glioblastomas1
1RecruitingTreatmentGlioblastomas1
1RecruitingTreatmentGlioblastomas / Gliosarcoma1
1RecruitingTreatmentPrimary Brain Tumors / Tumors, Solid1
1RecruitingTreatmentSarcoma, Ewing's2
1RecruitingTreatmentSolid Tumors, Glioblastoma, Recurrent Malignant Gliomas1
1TerminatedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Glioblastomas / Gliosarcoma1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentBrain Diseases / CNS Disease / Glioblastomas1
1TerminatedTreatmentBrain and Central Nervous System Tumors1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentCentral Nervous System Neoplasms / Neoplasms Metastasis1
1TerminatedTreatmentGlioblastoma Multiforme1
1TerminatedTreatmentMelanoma1
1TerminatedTreatmentMetastases, Brain1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentNeoplastic Meningitis1
1WithdrawnTreatmentGlioblastoma Multiforme1
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
1, 2Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Cognitive/Functional Effects1
1, 2Active Not RecruitingTreatmentAdult Glioblastoma1
1, 2Active Not RecruitingTreatmentAnaplastic Gliomas / Glioblastoma Multiforme1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors7
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS1
1, 2Active Not RecruitingTreatmentCancer of Brain and Nervous System / Glioblastoma Multiforme / Glioblastomas1
1, 2Active Not RecruitingTreatmentChildhood Mixed Glioma / Untreated Childhood Anaplastic Astrocytoma / Untreated Childhood Brain Stem Glioma / Untreated Childhood Fibrillary Astrocytoma / Untreated Childhood Giant Cell Glioblastoma / Untreated Childhood Glioblastoma / Untreated Childhood Gliosarcoma1
1, 2Active Not RecruitingTreatmentGlioblastoma Multiforme / Gliosarcoma1
1, 2Active Not RecruitingTreatmentGlioblastomas1
1, 2Active Not RecruitingTreatmentGliomas1
1, 2Active Not RecruitingTreatmentMalignant Gliomas1
1, 2Active Not RecruitingTreatmentMelanoma2
1, 2Active Not RecruitingTreatmentMelanoma (Skin)1
1, 2Active Not RecruitingTreatmentMetastatic Melanoma2
1, 2Active Not RecruitingTreatmentNeuroblastomas1
1, 2Active Not RecruitingTreatmentPancreatic Neuroendocrine Tumors (pNET)1
1, 2Active Not RecruitingTreatmentPatients With Newly Diagnosed Glioblastoma1
1, 2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma2
1, 2CompletedTreatmentAdvanced Melanoma / Melanoma1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors3
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Head and Neck Cancers / Kidney Cancer / Neuroblastomas / Sarcomas / Testicular germ cell tumour1
1, 2CompletedTreatmentGlioblastoma Multiforme1
1, 2CompletedTreatmentGlioblastoma Multiforme / Glioblastomas / Gliosarcoma1
1, 2CompletedTreatmentGlioblastomas / Tumor, Brain1
1, 2CompletedTreatmentIntraocular Melanoma / Melanoma (Skin)1
1, 2CompletedTreatmentMalignant Melanoma1
1, 2CompletedTreatmentMetastases, Brain / Tumor, Brain1
1, 2CompletedTreatmentMetastatic Cancers1
1, 2CompletedTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentRecurrent Melanoma / Stage IV Skin Melanoma1
1, 2CompletedTreatmentSarcoma, Ewing's1
1, 2Not Yet RecruitingNot AvailableCytokine-Induced Killer Cells / Milignant Gliomas1
1, 2Not Yet RecruitingPreventionNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2Not Yet RecruitingTreatmentGlioblastoma Multiforme1
1, 2RecruitingTreatmentActivation of the Sonic Hedgehog (SHH) Pathway / Histologically Confirmed Medulloblastoma1
1, 2RecruitingTreatmentAdult Ependymoblastoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Medulloblastoma / Adult Mixed Glioma / Adult Oligodendroglial Tumors / Adult Pineoblastoma / Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)1
1, 2RecruitingTreatmentAdult Glioblastoma1
1, 2RecruitingTreatmentAdult Glioblastoma / Adult Gliosarcoma1
1, 2RecruitingTreatmentAdult Solid Neoplasm / Childhood Solid Neoplasm / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Refractory Central Nervous System Neoplasm1
1, 2RecruitingTreatmentAnaplastic Astrocytoma (AA) / Brainstem Glioma / Diffuse Intrinsic Pontine Glioma (DIPG) / DIPG / Glioblastoma Multiforme / Glioma, Astrocytic / Gliosarcoma / Low-Grade Gliomas / Optic Nerve Glioma / Pilocytic Astrocytoma / Pilomyxoid Astrocytoma / Pleomorphic Xanthoastrocytoma1
1, 2RecruitingTreatmentAstrocytomas / Astroglioma / Glioblastomas / Gliosarcoma / Tumor, Brain1
1, 2RecruitingTreatmentGlioblastoma Multiforme3
1, 2RecruitingTreatmentGlioblastoma Multiforme / Gliomas / Gliosarcoma / Malignant Brain Tumors1
1, 2RecruitingTreatmentGlioblastomas2
1, 2RecruitingTreatmentGlioblastomas (GBM)1
1, 2RecruitingTreatmentHigh Grade Glioma, Glioblastoma1
1, 2RecruitingTreatmentPancreatic Alpha Cell Carcinoma / Pancreatic Beta Islet Cell Carcinoma / Pancreatic Delta Cell Carcinoma / Pancreatic G-cell Carcinoma / Recurrent Islet Cell Carcinoma1
1, 2RecruitingTreatmentSmall Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentAstrocytomas / Glioblastoma Multiforme / Gliomas / Tumor, Brain1
1, 2TerminatedTreatmentBrain Cancer / Glioblastoma Multiforme1
1, 2TerminatedTreatmentBrain and Central Nervous System Tumors / Melanoma / Tumors, Solid1
1, 2TerminatedTreatmentGlioblastoma Multiforme1
1, 2TerminatedTreatmentMelanoma1
1, 2TerminatedTreatmentMetastatic Malignant Melanoma2
1, 2TerminatedTreatmentNeuroblastomas1
1, 2WithdrawnTreatmentBrain and Central Nervous System Tumors1
1, 2WithdrawnTreatmentMetastases, Brain / Metastatic Melanoma1
2Active Not RecruitingTreatmentAdult Glioblastoma / Adult Gliosarcoma1
2Active Not RecruitingTreatmentAnaplastic Glioma of Brain / Loss of Chromosomes 1p/19q1
2Active Not RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Cancer, Breast / Metastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors10
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentCancer, Ovarian / Endometrial Cancers / Sarcomas1
2Active Not RecruitingTreatmentCarcinoma, Islet Cell / Gastrinoma / Glucagonoma / Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Somatostatinoma1
2Active Not RecruitingTreatmentCarcinoma, Small Cell1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2Active Not RecruitingTreatmentGiant Cell Glioblastoma / Glioblastomas / Gliosarcoma1
2Active Not RecruitingTreatmentGlioblastoma Multiforme1
2Active Not RecruitingTreatmentGlioblastoma Multiforme / Gliosarcoma1
2Active Not RecruitingTreatmentGlioblastoma Multiforme / Gliosarcoma / Malignant Gliomas1
2Active Not RecruitingTreatmentGlioblastomas / Gliomas1
2Active Not RecruitingTreatmentGlioblastomas / Gliosarcoma / Grade 4 Malignant Glioma / Malignant Gliomas1
2Active Not RecruitingTreatmentGliomas3
2Active Not RecruitingTreatmentHepatocellular Carcinomas1
2Active Not RecruitingTreatmentHigh Grade Gliomas / Tumor, Brain1
2Active Not RecruitingTreatmentIris Melanoma / Medium/Large Size Posterior Uveal Melanoma / Ocular Melanoma With Extraocular Extension / Recurrent Uveal Melanoma / Small Size Posterior Uveal Melanoma / Stage IV Uveal Melanoma1
2Active Not RecruitingTreatmentMalignant Gliomas1
2Active Not RecruitingTreatmentMalignant Melanoma2
2Active Not RecruitingTreatmentMalignant Neoplasms of Brain1
2Active Not RecruitingTreatmentMelanoma2
2Active Not RecruitingTreatmentMelanoma (Skin)1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic Melanoma1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentNeurofibromatosis 11
2Active Not RecruitingTreatmentNewly Diagnosed Supratentorial Malignant Glioma1
2Active Not RecruitingTreatmentRecurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentRecurrent Glioblastoma Multiforme / Recurrent Gliosarcoma1
2Active Not RecruitingTreatmentRecurrent Small Cell Lung Carcinoma1
2Active Not RecruitingTreatmentRecurrent Uveal Melanoma / Stage IIIA Uveal Melanoma / Stage IIIB Uveal Melanoma / Stage IIIC Uveal Melanoma / Stage IV Uveal Melanoma1
2Active Not RecruitingTreatmentSarcomas1
2Active Not RecruitingTreatmentSpinal Cord Tumors / Tumor, Brain1
2Active Not RecruitingTreatmentTumor, Brain / Tumors, Central Nervous System2
2Active Not RecruitingTreatmentTumors, Central Nervous System3
2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
2CompletedTreatmentAdult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas1
2CompletedTreatmentAnaplastic Glioma of Brain / Brain Cancer / Glioblastoma Multiforme1
2CompletedTreatmentAnaplastic Oligodendroglioma (AO) / Oligoastrocytoma, Mixed1
2CompletedTreatmentAstrocytomas1
2CompletedTreatmentAstrocytomas / Brain Tumor, Recurrent / Glioblastomas / Oligodendrogliomas1
2CompletedTreatmentAstrocytomas / Glioblastomas / Gliomas / Oligodendrogliomas1
2CompletedTreatmentAstrocytomas / Gliomas / Oligodendrogliomas1
2CompletedTreatmentBrain and Central Nervous System Tumors17
2CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2CompletedTreatmentBrain and Central Nervous System Tumors / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentCNS Tumor, Adult2
2CompletedTreatmentCancer, Breast / Metastatic Cancers1
2CompletedTreatmentCancer, Breast / Soft Tissue Sarcoma (STS)1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentCancer, Ovarian / Testicular germ cell tumour1
2CompletedTreatmentCancers / Melanoma / Skin Cancers1
2CompletedTreatmentCancers / Metastases, Brain1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Neuroblastomas1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentGastrointestinal Stromal Tumors1
2CompletedTreatmentGlioblastoma Multiforme10
2CompletedTreatmentGlioblastoma Multiforme / Gliosarcoma2
2CompletedTreatmentGlioblastomas5
2CompletedTreatmentGlioblastomas / Gliosarcoma4
2CompletedTreatmentGlioblastomas / Gliosarcoma / Tumor, Brain1
2CompletedTreatmentGlioblastomas / Primary Brain Tumors1
2CompletedTreatmentGliomas2
2CompletedTreatmentGliomas / Medulloblastomas1
2CompletedTreatmentIntraocular Melanoma / Melanoma (Skin)2
2CompletedTreatmentLung Cancers5
2CompletedTreatmentLung Cancers / Metastatic Cancers2
2CompletedTreatmentLymphoma NOS2
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentMelanoma3
2CompletedTreatmentMelanoma (Skin)5
2CompletedTreatmentMelanoma (Skin) / Metastatic Cancers1
2CompletedTreatmentMelanoma / Metastases of Central Nervous System / Neoplasms, Breast / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMelanoma / Metastatic Melanoma / Skin Cancers1
2CompletedTreatmentMelanoma / Skin Cancers1
2CompletedTreatmentMetastases, Brain1
2CompletedTreatmentMetastatic Cancers1
2CompletedTreatmentMyeloid Leukemias1
2CompletedTreatmentNaive Unresectable Glioblastoma1
2CompletedTreatmentNeoplasm Metastases / Neoplasms, Brain / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Brain / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNeoplasms, Brain1
2CompletedTreatmentNeuroblastomas2
2CompletedTreatmentNeuroendocrine Tumors3
2CompletedTreatmentRecurrent Central Nervous System Neoplasm1
2CompletedTreatmentRecurrent Glioblastoma Multiforme2
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma / Tumors Metastatic to Brain1
2CompletedTreatmentSolid Tumor Cancers1
2CompletedTreatmentTumor, Brain1
2Not Yet RecruitingTreatmentEpendymomas / Gliomas / Medulloblastomas / Neuroectodermal Tumors / Osteosarcomas / Rhabdomyosarcomas / Sarcoma, Ewing's / Wilms Tumor1
2Not Yet RecruitingTreatmentGlioblastoma Multiforme2
2Not Yet RecruitingTreatmentGlioblastomas3
2Not Yet RecruitingTreatmentGlioblastomas / Gliosarcoma1
2Not Yet RecruitingTreatmentGliomas1
2Not Yet RecruitingTreatmentMidgut Neuroendocrine Tumours / Pancreatic Neuroendocrine Tumors (pNET)1
2Not Yet RecruitingTreatmentNeuroendocrine Tumours1
2Not Yet RecruitingTreatmentPineoblastoma1
2RecruitingDiagnosticAdult Anaplastic (Malignant) Meningioma / Adult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Brain Stem Glioma / Adult Choroid Plexus Neoplasm / Adult Ependymoblastoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Medulloblastoma / Adult Mixed Glioma / Adult Papillary Meningioma / Adult Pineal Gland Astrocytoma / Adult Pineoblastoma / Adult Primary Melanocytic Lesion of Meninges / Adult Supratentorial Primitive Neuroectodermal Tumor1
2RecruitingDiagnosticMalignant Gliomas1
2RecruitingTreatmentAcute Myeloid Leukemia With 11q23-abnormality in Relapse1
2RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma1
2RecruitingTreatmentAdult Brain Glioblastoma1
2RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
2RecruitingTreatmentAnaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO)1
2RecruitingTreatmentAstrocytoma, Grade IV / Giant Cell Glioblastoma / Glioblastoma Multiforme / Glioblastomas1
2RecruitingTreatmentAstrocytomas / Oligoastrocytoma / Oligodendrogliomas1
2RecruitingTreatmentB-Cell Lymphoma Originating in the CNS1
2RecruitingTreatmentBrain and Central Nervous System Tumors2
2RecruitingTreatmentCancer, Breast / Metastatic Cancers1
2RecruitingTreatmentCentral Nervous System (CNS) Metastases / Metastases, Brain1
2RecruitingTreatmentChildhood Brain Stem Neoplasm1
2RecruitingTreatmentColorectal Large Cell Neuroendocrine Carcinoma / Esophageal Large Cell Neuroendocrine Carcinoma / Gallbladder Large Cell Neuroendocrine Carcinoma / Gastric Large Cell Neuroendocrine Carcinoma / Pancreatic Large Cell Neuroendocrine Carcinoma / Small Intestinal Large Cell Neuroendocrine Carcinoma1
2RecruitingTreatmentExtensive Stage Small Cell Lung Cancer1
2RecruitingTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma1
2RecruitingTreatmentGastrinoma / Glucagonoma / Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Recurrent Pancreatic Cancer / Somatostatinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2RecruitingTreatmentGastroenteropancreatic Neuroendocrine Tumors1
2RecruitingTreatmentGlioblastoma Multiforme5
2RecruitingTreatmentGlioblastoma Multiforme of Brain1
2RecruitingTreatmentGlioblastomas6
2RecruitingTreatmentGlioblastomas / Gliosarcoma2
2RecruitingTreatmentGliomas1
2RecruitingTreatmentHigh Grade Glioma (HGG)1
2RecruitingTreatmentHigh-Grade Gliomas1
2RecruitingTreatmentIntraocular Melanoma1
2RecruitingTreatmentLow Grade Glioma (LGG) / Oligoastrocytoma, Mixed / Oligodendrogliomas / WHO Grade II Astrocytomas1
2RecruitingTreatmentLymphoma NOS1
2RecruitingTreatmentMalignant Gliomas1
2RecruitingTreatmentMalignant Melanoma1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentMetastatic Carcinoma / Small Cell Lung Cancer (SCLC)1
2RecruitingTreatmentMetastatic Colorectal Cancers1
2RecruitingTreatmentNeoplasms, Brain1
2RecruitingTreatmentNeuroblastoma Recurrent1
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentNeuroendocrine Carcinomas1
2RecruitingTreatmentNewly Diagnosed Ewing Sarcoma1
2RecruitingTreatmentNewly Diagnosed Non Methylated Glioblastoma Multiforme Grade 41
2RecruitingTreatmentPrimary Central Nervous System Lymphoma (PCNSL)2
2RecruitingTreatmentRetinoblastoma1
2RecruitingTreatmentRefractory Small cell lung cancer1
2SuspendedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2TerminatedPreventionNeoplasms, Brain / Neoplasms, Breast / Second Neoplasm1
2TerminatedTreatmentAdenocarcinomas / Carcinoma, Large Cell / Non-Small-Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentAstrocytomas / Gliomas / Oligoastrocytoma / Oligodendrogliomas1
2TerminatedTreatmentBone Cancer / Sarcoma, Ewing's1
2TerminatedTreatmentBrain Cancer1
2TerminatedTreatmentBrain and Central Nervous System Tumors1
2TerminatedTreatmentGlioblastoma Multiforme2
2TerminatedTreatmentGlioblastoma Multiforme / High-Grade Gliomas1
2TerminatedTreatmentGlioblastomas / Gliosarcoma1
2TerminatedTreatmentGliomas1
2TerminatedTreatmentLeptomeningeal Metastases / Tumor, Brain / Tumors, Central Nervous System1
2TerminatedTreatmentLymphoma NOS1
2TerminatedTreatmentMelanoma2
2TerminatedTreatmentMelanoma (Skin)1
2TerminatedTreatmentMetastases, Brain1
2TerminatedTreatmentNeoplasms, Colorectal / Neoplasms, Esophageal / Neoplasms, Head and Neck / Non-Small-Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2WithdrawnTreatmentBrain Diseases / CNS Disease / Glioblastomas1
2WithdrawnTreatmentBrain and Central Nervous System Tumors2
2WithdrawnTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas1
2WithdrawnTreatmentGlioblastomas / Gliosarcoma1
2WithdrawnTreatmentLung Cancers / Metastatic Cancers1
2WithdrawnTreatmentMelanoma / Neoplasms, Brain1
2WithdrawnTreatmentSoft Tissue Sarcoma (STS)1
2, 3Active Not RecruitingTreatmentChildhood Cerebellar Anaplastic Astrocytoma / Childhood Cerebral Anaplastic Astrocytoma / Childhood Spinal Cord Neoplasm / Untreated Childhood Brain Stem Glioma / Untreated Childhood Cerebral Astrocytoma1
2, 3Active Not RecruitingTreatmentEpendymomas / Medulloblastomas / Recurrent Brain Tumors / Supratentorial PNETs1
2, 3Not Yet RecruitingTreatmentGlioblastomas1
2, 3RecruitingTreatmentAnaplastic Astrocytoma (AA) / Glioblastoma Multiforme1
2, 3SuspendedTreatmentGlioblastomas / Gliosarcoma1
3Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Cognitive Side Effects of Cancer Therapy1
3Active Not RecruitingTreatmentBrain and Central Nervous System Tumors4
3Active Not RecruitingTreatmentGiant Cell Glioblastoma / Glioblastoma With Oligodendroglial Component / Glioblastomas / Gliosarcoma / Small Cell Glioblastoma1
3Active Not RecruitingTreatmentGlioblastoma Multiforme1
3Active Not RecruitingTreatmentGlioblastomas1
3CompletedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas1
3CompletedTreatmentAnaplastic Astrocytoma (AA) / Oligoastrocytoma / Oligodendrogliomas1
3CompletedTreatmentAstrocytomas / Glioblastomas1
3CompletedTreatmentBrain and Central Nervous System Tumors4
3CompletedTreatmentGlioblastomas4
3CompletedTreatmentMelanoma2
3CompletedTreatmentMetastatic Melanoma1
3Not Yet RecruitingTreatmentGlioblastomas1
3Not Yet RecruitingTreatmentPrimary CNS Lymphoma1
3RecruitingNot AvailableNeoplasms Metastasis / Non-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Glioblastomas1
3RecruitingTreatmentAstrocytomas / Oligodendroastrocytoma / Oligodendrogliomas1
3RecruitingTreatmentBrain Cancer1
3RecruitingTreatmentBrain and Central Nervous System Tumors1
3RecruitingTreatmentBrain and Central Nervous System Tumors / Neurotoxicity1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3TerminatedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas1
3TerminatedTreatmentAstrocytomas / Oligoastrocytoma / Oligodendrogliomas1
3TerminatedTreatmentGlioblastoma Multiforme1
3TerminatedTreatmentMelanoma (Skin) / Metastatic Cancers1
3TerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Tumors Metastatic to Brain1
3WithdrawnTreatmentOptic Nerve Glioma1
3WithdrawnTreatmentRecurrent Glioblastoma1
4CompletedTreatmentBrain Neoplasms, Malignant, Primary1
4CompletedTreatmentGlioblastomas1
4Not Yet RecruitingNot AvailableAdvanced Milignant Gliomas / Cytokine-Induced Killer Cells1
Not AvailableActive Not RecruitingNot AvailableAstrocytomas / Gliomas1
Not AvailableActive Not RecruitingTreatmentBrain and Central Nervous System Tumors / Thrombocytopenias1
Not AvailableActive Not RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG) / Newly Diagnosed High-Grade Gliomas1
Not AvailableCompletedNot AvailableAstrocytomas / Glioblastomas / Gliomas1
Not AvailableCompletedNot AvailableGlioblastomas3
Not AvailableCompletedDiagnosticAdult Glioblastoma / Depression / Recurrent Adult Brain Tumor1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Metastatic Cancers1
Not AvailableCompletedTreatmentGlioblastoma Mutliforme1
Not AvailableCompletedTreatmentTumor, Brain / Tumors, Central Nervous System1
Not AvailableNot Yet RecruitingTreatmentRecurrent High-grade Glioma1
Not AvailableRecruitingNot AvailableGlioblastomas1
Not AvailableRecruitingTreatmentGlioblastomas1
Not AvailableRecruitingTreatmentNeoplasms / Neoplasms, Advanced Solid / Recurrent Solid Neoplasm1
Not AvailableRecruitingTreatmentRecurrent Childhood Brain Tumor1
Not AvailableSuspendedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
Not AvailableTerminatedNot AvailableBrain and Central Nervous System Tumors1
Not AvailableWithdrawnNot AvailableAstrocytoma, Grade IV / Giant Cell Glioblastoma / Glioblastoma Multiforme1
Not AvailableWithdrawnTreatmentLymphoma NOS / Tumors, Central Nervous System1
PharmacodynamicsTemozolomide is an imidazotetrazine deritave and an antineoplastic agent. It is a prodrug that has little to no pharmacological activity until it is hydrolyzed in vivo to 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). After administration, temozolomide undergoes rapid, nonenzymatic hydrolysis at physiological pH to MTIC, which is the active form of the drug. MTIC is generated through the effect of water at the highly electropositive C4 position of temozolomide, causing the ring of temozolomide to open, release carbon dioxide, and generate MTIC.
Mechanism of actionTemozolomide is not active until it is converted at physiologic pH to MTIC. It is suggested that MTIC then alkylates DNA at the N7 position of guanine, O3 position of adenosine, and O6 position of guanosine, with the most common site being the N7 position. This methylation of guanine residues lead to single and double-strand DNA breaks and subsequent apoptotic cell death. It is suggested that the N7-methylguanine plays a critical role in the antitumor activity of the drug, as there is a correlation between the sensitivity of tumor cell lines to temozolomide and the activity of O6-alkylguanine alkyltransferase, which is the DNA repair protein that specifically removes alkyl groups at the O6 position of guanine. Cells lines that have lower levels of AGT are more sensitive to the cytotoxicity of temozolomide. It is also suggested that cytotoxic mechanism of temozolomide is related to the failure of the DNA MMR system to find a complementary base for methylated guanine. The DNA MMR system is involved in the formation of a number of proteins that remove methylated guanine. Evidence shows that when this repair process is targeted to the DNA strand opposite the O6-methylguanine, its inability to find the correct target leads to long-lived nicks in the DNA. The accumulation of these nicks lead to the inhibition of replication in the daughter cells, thereby blocking the cell cycle at the G2-M boundary.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
Related Articles
AbsorptionRapid and complete absorption in the gastrointestinal tract
Volume of distribution
  • 0.4 L/kg
Protein binding15%
MetabolismNot Available
Route of eliminationAbout 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 37.7% in urine and 0.8% in feces.
Half lifeApproximately 1.8 hours.
Clearance
  • 5.5 L/hr/m2
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Temozolomide.Approved
ALT-110The risk or severity of adverse effects can be increased when Temozolomide is combined with ALT-110.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Temozolomide.Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Temozolomide.Approved, Investigational
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Temozolomide.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Temozolomide.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temozolomide.Approved
CDX-110The risk or severity of adverse effects can be increased when Temozolomide is combined with CDX-110.Investigational
ClozapineThe risk or severity of adverse effects can be increased when Temozolomide is combined with Clozapine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Temozolomide.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Temozolomide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Temozolomide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Temozolomide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Temozolomide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temozolomide.Approved, Investigational
FingolimodTemozolomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Temozolomide is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Temozolomide is combined with GI-5005.Investigational
INGN 201The risk or severity of adverse effects can be increased when Temozolomide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Temozolomide is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Leflunomide.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Temozolomide.Withdrawn
NatalizumabThe risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Temozolomide.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temozolomide.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temozolomide.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Temozolomide is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Temozolomide.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Temozolomide.Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Temozolomide.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temozolomide.Approved
SRP 299The risk or severity of adverse effects can be increased when Temozolomide is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Temozolomide.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Temozolomide is combined with TG4010.Investigational
TofacitinibTemozolomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Temozolomide.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Temozolomide.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Shen-Chun Kuo, “Synthesis of temozolomide and analogs.” U.S. Patent US20020133006, issued September 19, 2002.

US20020133006
General References
  1. Neyns B, Tosoni A, Hwu WJ, Reardon DA: Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15;116(12):2868-77. doi: 10.1002/cncr.25035. [PubMed:20564393 ]
  2. Wick W, Platten M, Weller M: New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009 Feb;11(1):69-79. doi: 10.1215/15228517-2008-078. Epub 2008 Sep 4. [PubMed:18772354 ]
  3. Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55. doi: 10.1007/s00280-009-1050-5. Epub 2009 Jun 19. [PubMed:19543728 ]
  4. Meije Y, Lizasoain M, Garcia-Reyne A, Martinez P, Rodriguez V, Lopez-Medrano F, Juan RS, Lalueza A, Aguado JM: Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis. 2010 Jun 15;50(12):e73-6. doi: 10.1086/653011. [PubMed:20455691 ]
  5. Trinh VA, Patel SP, Hwu WJ: The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf. 2009 Jul;8(4):493-9. doi: 10.1517/14740330902918281 . [PubMed:19435405 ]
  6. Yung WK: Temozolomide in malignant gliomas. Semin Oncol. 2000 Jun;27(3 Suppl 6):27-34. [PubMed:10866347 ]
  7. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. [PubMed:10914698 ]
  8. Mutter N, Stupp R: Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther. 2006 Aug;6(8):1187-204. [PubMed:16925485 ]
External Links
ATC CodesL01AX03
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (67.2 KB)
MSDSDownload (58 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9879
Caco-2 permeable+0.5608
P-glycoprotein substrateNon-substrate0.7228
P-glycoprotein inhibitor INon-inhibitor0.9255
P-glycoprotein inhibitor IINon-inhibitor0.9823
Renal organic cation transporterNon-inhibitor0.8822
CYP450 2C9 substrateNon-substrate0.7948
CYP450 2D6 substrateNon-substrate0.8695
CYP450 3A4 substrateNon-substrate0.5855
CYP450 1A2 substrateNon-inhibitor0.8134
CYP450 2C9 inhibitorNon-inhibitor0.9753
CYP450 2D6 inhibitorNon-inhibitor0.9479
CYP450 2C19 inhibitorNon-inhibitor0.9522
CYP450 3A4 inhibitorNon-inhibitor0.9571
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9954
Ames testNon AMES toxic0.5322
CarcinogenicityNon-carcinogens0.9412
BiodegradationNot ready biodegradable0.5172
Rat acute toxicity2.5279 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7553
hERG inhibition (predictor II)Non-inhibitor0.9242
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering corp
  • Barr laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral180 mg
CapsuleOral100 mg
CapsuleOral140 mg
CapsuleOral20 mg
CapsuleOral250 mg
CapsuleOral5 mg
Injection, powder, for solutionIntravenous2.5 mg/ml
Powder, for solutionIntravenous100 mg
CapsuleOral100 mg/1
CapsuleOral140 mg/1
CapsuleOral180 mg/1
CapsuleOral20 mg/1
CapsuleOral250 mg/1
CapsuleOral5 mg/1
Injection, powder, lyophilized, for solutionIntravenous2.5 mg/mL
Prices
Unit descriptionCostUnit
Temodar 250 mg capsule466.11USD capsule
Temodar 180 mg capsule401.53USD capsule
Temodar 100 mg capsule223.07USD capsule
Temodar 20 mg capsule44.62USD capsule
Temodar 5 mg capsule10.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2066313 No2002-08-202012-04-16Canada
CA2476494 No2010-04-272023-02-20Canada
US5260291 No1993-08-112013-08-11Us
US6987108 No2003-09-082023-09-08Us
US7786118 No2003-02-212023-02-21Us
US8623868 No2003-02-212023-02-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point212 °CNot Available
logP-2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.09 mg/mLALOGPS
logP-1ALOGPS
logP-0.28ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)10.51ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area105.94 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity47.86 m3·mol-1ChemAxon
Polarizability16.88 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as imidazotetrazines. These are organic polycyclic compounds containing an imidazole ring fused to a tetrazine ring. Imidazole is 5-membered ring consisting of three carbon atoms, and two nitrogen centers at the 1- and 3-positions. Tetrazine is a six-membered aromatic heterocycle made up of four nitrogen atoms and a two carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassImidazotetrazines
Sub ClassNot Available
Direct ParentImidazotetrazines
Alternative Parents
Substituents
  • Imidazotetrazine
  • 2-heteroaryl carboxamide
  • Imidazole-4-carbonyl group
  • N-substituted imidazole
  • Tetrazine
  • Azole
  • Imidazole
  • Heteroaromatic compound
  • Vinylogous amide
  • Carboxamide group
  • Primary carboxylic acid amide
  • Carboxylic acid derivative
  • Azacycle
  • Organooxygen compound
  • Organonitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Zaremba T, Curtin NJ: PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem. 2007 Sep;7(5):515-23. [PubMed:17896912 ]
  4. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD: Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg. 2007 Sep;107(3):610-6. [PubMed:17886562 ]
  5. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L: Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res. 2007 Oct;56(4):275-87. Epub 2007 Aug 9. [PubMed:17897837 ]
  6. Neyns B, Tosoni A, Hwu WJ, Reardon DA: Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15;116(12):2868-77. doi: 10.1002/cncr.25035. [PubMed:20564393 ]
  7. Wick W, Platten M, Weller M: New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009 Feb;11(1):69-79. doi: 10.1215/15228517-2008-078. Epub 2008 Sep 4. [PubMed:18772354 ]
  8. Natelson EA, Pyatt D: Temozolomide-induced myelodysplasia. Adv Hematol. 2010;2010:760402. doi: 10.1155/2010/760402. Epub 2010 Mar 4. [PubMed:20224797 ]
  9. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. [PubMed:10914698 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 19, 2017 02:43